Emerging immunologic approaches as cancer anti-angiogenic therapies
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03667-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Mohammadreza Azimi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Medical Faculty, Saveh Branch, Islamic Azad University, Saveh, Iran. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Neoplasms, Neovascularization, Pathologic, Immunotherapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 142 Literaturangaben.
Abstract (Originalsprache)
Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system's specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Medical Faculty, Saveh Branch, Islamic Azad University, Saveh, Iran.
- Otolaryngology Department, Tehran University of Medical Science, Tehran, Iran.
- Department of Chemistry and Biochemistry, South Dakota State University (SDSU), Brookings, SD, USA.
- Bone and Joint Diseases Research Center, Department of Orthopedic Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Orthopeadic Surgery, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
Zitieren
APA
Azimi, M., Manavi, M. S., Afshinpour, M., Khorram, R., Vafadar, R., Rezaei-Tazangi, F., Arabzadeh, D., Arabzadeh, S., Ebrahimi, N., & Aref, A. R. (2024). Emerging immunologic approaches as cancer anti-angiogenic therapies. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03667-2
Vancouver
Azimi M, Manavi MS, Afshinpour M, Khorram R, Vafadar R, Rezaei-Tazangi F, et al. Emerging immunologic approaches as cancer anti-angiogenic therapies. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03667-2
BibTeX
@article{Azimi2024,
author = {Azimi, Mohammadreza and Manavi, Mahdokht Sadat and Afshinpour, Maral and Khorram, Roya and Vafadar, Reza and Rezaei-Tazangi, Fatemeh and Arabzadeh, Danyal and Arabzadeh, Sattar and Ebrahimi, Nasim and Aref, Amir Reza},
title = {Emerging immunologic approaches as cancer anti-angiogenic therapies},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03667-2}
}
EUVIMED